The more cases there are, the more opportunities for the virus to mutate—for better or for worse. There is no guarantee that future mutations will gradually make the virus milder. “We’ll see other variants,” said Reinhart, who is also a physician at Northwestern University. “Some of them may evade testing, some of them may evade the vaccines, some may be more deadly.”

Vaccine protection

To stop the virus from mutating, rich countries will have to do a lot better in helping the rest of the world get jabbed.

In 2021, G7 and EU countries had a supply of more than 3 billion vaccines, according to data from the Covid Global Accountability Platform, a watchdog group out of Duke University. Assuming the countries vaccinated 75% of their population, boosted another 20%, donated some 400 million doses, and wasted 10% of their supplies, they would have around 770 million vaccines to spare. That’s more than were needed to meet the World Health Organization goal of covering 40% of the world’s population by the end of 2021. As of late December 98 countries were falling short of that goal.

Omicron will likely set global vaccination efforts further back. Early research suggests that two doses of an mRNA vaccine are far less effective against an omicron infection than they are against delta. A third shot is needed to increase protection. According to the models put together by UT Austin researchers, boosters could prevent hundreds of thousands of cases and tens of thousands of deaths if 80% of vaccinated Americans get them by March.

But while that might be attainable in the US, it looks well out of reach for poor countries where residents are yet to receive their first dose.

The response

Though each variant is different, after two years of living with the virus we know enough to control it, researchers say. At the top of public health experts’ wish list for politicians is upping vaccine distribution around the world, though masking, social distancing, and widespread testing are also needed. “The challenge before us today isn’t a scientific problem,” said Akshita Siddula, co-founder of Right to Health Action, an advocacy group, during a recent online conference. “What we have here in front of us is a problem of politics and power.”

In 2022, governments will most likely have an additional pandemic-fighting tool: new covid antiviral drugs that promise to prevent the worst of the virus’s effects. Whether the pills put a dent in the pandemic will also depend on how policymakers in the world’s most powerful countries allocate supplies. Pfizer and Merck have already inked licensing agreements with poor regions so factories there can manufacture the drugs, according to data compiled by Covid GAP.  But the drugs Merck and Pfizer produce themselves will likely go to rich countries first, based on the supply deals they’ve already signed.

A huge global wave of omicron cases, which some experts are expecting, might stave off the pandemic for some time. Early research suggests an omicron infection boosts immunity to the delta variant, which could be displaced. And populations are likely to quickly build up immunity to omicron itself, given how fast it spreads and how many it could infect.

Still, to avoid bumbling from variant to variant in 2022, policymakers will have to change their approach from containment to prevention, and from local to global. That’s not only needed to get this virus under control, but to do better when the next one hits. “It’s not going to be long before we’re facing down another pandemic,” said Siddula. “Covid the sequel.”

📬 Sign up for the Daily Brief

Our free, fast, and fun briefing on the global economy, delivered every weekday morning.